TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients

被引:0
|
作者
Parham Jazireian
Soheila Talesh Sasani
Farhad Assarzadegan
Mojtaba Azimian
机构
[1] University Campus 2,Department of Biology
[2] University of Guilan,Department of Biology, Faculty of Sciences
[3] University of Guilan,Department of Neurology
[4] Imam Hossein Hospital,undefined
[5] Shahid Beheshti University of Medical Sciences,undefined
[6] Rofeydeh Rehabilitation Center,undefined
[7] University of Social Welfare and Rehabilitation Sciences,undefined
来源
Molecular Biology Reports | 2020年 / 47卷
关键词
Pharmacogenetics; Multiple sclerosis; Gene polymorphisms; Interferon-β;
D O I
暂无
中图分类号
学科分类号
摘要
Multiple sclerosis (MS) is an autoimmune-type inflammatory disorder in human central nervous system. Recombinant interferon beta (IFN-β) decreases the number of relapses and postpones disability progression in MS. However, up to 50% of patients treated with interferon beta continue experiencing relapses and/or worsening disability. Single nucleotide polymorphisms in different genes have been known to show significant associations with response to IFN-β in MS patients. In the present work, we examined the potential role of TRAILR1 and GRIA3 genes polymorphisms on response to IFN-β therapy in Iranian MS patients. The DNA was extracted from blood samples by standard procedures from 73 patients diagnosed with Multiple Sclerosis that were either responded to IFN-β or did not. We carried out RFLP -PCR and tetra-primer ARMS-PCR methods to study of rs20576 and rs12557782, respectively. All results were analyzed using the SPSS software. TRAILR1 rs20576 genotype frequencies in responders and non-responders were similar (χ2 = 0.26, P = 0.87, Fisher, s Exact test). Our results showed that response to IFN-β has not association with sex (p = 0.73). Also, genotypic frequencies of GRIA3 rs12557782 had no significant differences between two groups of female population (χ2 = 3.75, p = 0.15). Furthermore, it had not been any statistical differences between responder and non-responder males (χ2 = 0.7, p = 0.4) related to the SNP. Our results analysis revealed no significant association between the studied SNPs (TRAILR1 rs20576 and GRIA3rs 12,557,782) and response to IFN-β in Iranian MS patients.
引用
收藏
页码:9659 / 9665
页数:6
相关论文
共 28 条
  • [1] TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients
    Jazireian, Parham
    Sasani, Soheila Talesh
    Assarzadegan, Farhad
    Azimian, Mojtaba
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (12) : 9659 - 9665
  • [2] Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger
    Gutierrez-Civicos, Rocio
    Hurtado, Ana M.
    Torres-Moreno, Daniel
    Sanchez-Blanco, Jose J.
    Espanol, Ignacio
    Consuegra-Sanchez, Luciano
    Perez-Ceballos, Elena
    Gutierrez-Meca, Maria D.
    Jerez, Andres
    Conesa-Zamora, Pablo
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (02): : 70 - 77
  • [3] Beneficial effect of interferon-β treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-β injection
    Nakatsuji, Y.
    Nakano, M.
    Moriya, M.
    Kishigami, H.
    Tatsumi, C.
    Tada, S.
    Sadahiro, S.
    Naka, T.
    Mitani, K.
    Funauchi, M.
    Azuma, T.
    Watanabe, S.
    Kinoshita, M.
    Kajiyama, K.
    Yuasa, Y.
    Kaido, M.
    Takahashi, M. P.
    Naba, I.
    Hazama, T.
    Sakoda, S.
    CYTOKINE, 2006, 36 (1-2) : 69 - 74
  • [4] Beneficial effect of interferon-β treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-β injection
    Nakatsuji, Y.
    Nakano, M.
    Moriya, M.
    Kishigami, H.
    Tatsumi, C.
    Tada, S.
    Sadahiro, S.
    Naka, T.
    Mitani, K.
    Funauchi, M.
    Azuma, T.
    Watanabe, S.
    Kinoshita, M.
    Kajiyama, K.
    Yuasa, Y.
    Kaido, M.
    Takahashi, MP.
    Naba, I.
    Hazama, T.
    Sakoda, S.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 207 - 208
  • [5] Chitinase 3-like 1 is associated with the response to interferon-beta in multiple sclerosis patients
    Matute, C.
    Rio, J.
    Villar, L. M.
    Malhotra, S.
    Alvarez-Cermeno, J. C.
    Montalban, X.
    Comabella, M.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 635 - 635
  • [6] The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients
    Flauzino, Tamires
    Alfieri, Daniela Frizon
    de Carvalho Jennings Pereira, Wildea Lice
    Oliveira, Sayonara Rangel
    Kallaur, Ana Paula
    Batisti Lozovoy, Marcell Alysson
    Kaimen-Maciel, Damacio Ramon
    de Oliveira, Karen Brajao
    Colado Simao, Andrea Name
    Vissoci Reiche, Edna Maria
    INFLAMMATION RESEARCH, 2019, 68 (11) : 933 - 943
  • [7] The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients
    Tamires Flauzino
    Daniela Frizon Alfieri
    Wildea Lice de Carvalho Jennings Pereira
    Sayonara Rangel Oliveira
    Ana Paula Kallaur
    Marcell Alysson Batisti Lozovoy
    Damacio Ramón Kaimen-Maciel
    Karen Brajão de Oliveira
    Andrea Name Colado Simão
    Edna Maria Vissoci Reiche
    Inflammation Research, 2019, 68 : 933 - 943
  • [8] PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients
    Qureshi, Moaz
    Hatem, Mohamed
    Alroughani, Raed
    Jacob, Sindhu P.
    Al-Temaimi, Rabeah Abbas
    NEUROMOLECULAR MEDICINE, 2017, 19 (2-3) : 286 - 292
  • [9] PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients
    Moaz Qureshi
    Mohamed Hatem
    Raed Alroughani
    Sindhu P. Jacob
    Rabeah Abbas Al-Temaimi
    NeuroMolecular Medicine, 2017, 19 : 286 - 292
  • [10] IFIH1 RS1990760 SNP IS ASSOCIATED WITH DIFFERENTIAL INTERFERON ALPHA RESPONSE AND DSDNA AUTOANTIBODIES IN LUPUS PATIENTS
    Robinson, T.
    Kariuki, S. N.
    Franek, B. S.
    Kumar, A. A.
    Badaracco, M.
    Utset, T. O.
    Niewold, T. B.
    Mikolaitis, R. A.
    Jolly, M.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2011, 59 (04) : 704 - 704